These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 29223437)

  • 41. Comparison of anti-thrombotic strategies using Bivalirudin, Heparin plus Glycoprotein IIb/IIIa inhibitors and Unfractionated Heparin Monotherapy for patients undergoing percutaneous coronary intervention - A single centre observational study.
    Kaul U; Dua A; Sethi AK; Arambam P; Seth A
    Indian Heart J; 2015; 67(4):311-7. PubMed ID: 26304562
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Safety of the primary percutaneous coronary intervention strategy combining pre-hospital prasugrel, enoxaparin and in-hospital bivalirudin in acute ST-segment elevation myocardial infarction.
    Viikilä J; Nieminen T; Tierala I; Laine M
    BMC Cardiovasc Disord; 2016 Jul; 16(1):154. PubMed ID: 27475059
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A prospective, randomized, open-label trial of 6-month versus 12-month dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction: Rationale and design of the "DAPT-STEMI trial".
    Kedhi E; Fabris E; van der Ent M; Kennedy MW; Buszman P; von Birgelen C; Cook S; Wedel H; Zijlstra F
    Am Heart J; 2017 Jun; 188():11-17. PubMed ID: 28577666
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparison of antithrombotic agents during urgent percutaneous coronary intervention following thrombolytic therapy: A retrospective cohort study.
    Mallidi JR; Robinson P; Visintainer PF; Lotfi AS; Mulvey S; Giugliano GR
    Catheter Cardiovasc Interv; 2017 Nov; 90(6):898-904. PubMed ID: 28417608
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Heparin monotherapy or bivalirudin during percutaneous coronary intervention in patients with non-ST-segment-elevation acute coronary syndromes or stable ischemic heart disease: results from the Evaluation of Drug-Eluting Stents and Ischemic Events registry.
    Bangalore S; Pencina MJ; Kleiman NS; Cohen DJ
    Circ Cardiovasc Interv; 2014 Jun; 7(3):365-73. PubMed ID: 24736878
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Periprocedural Bivalirudin Versus Unfractionated Heparin During Percutaneous Coronary Intervention Following Fibrinolysis for ST-Segment Elevation Myocardial Infarction.
    Rashid MK; Singh K; Bernick J; Wells GA; Hibbert B; Russo J; So DY; Le May MR;
    J Invasive Cardiol; 2019 Dec; 31(12):E387-E391. PubMed ID: 31786531
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Incidence, predictors, and implications of reinfarction after primary percutaneous coronary intervention in ST-segment-elevation myocardial infarction: the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction Trial.
    Stone SG; Serrao GW; Mehran R; Tomey MI; Witzenbichler B; Guagliumi G; Peruga JZ; Brodie BR; Dudek D; Möckel M; Brener SJ; Dangas G; Stone GW
    Circ Cardiovasc Interv; 2014 Aug; 7(4):543-51. PubMed ID: 24939928
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Impact of antithrombotic treatment on short-term outcomes after percutaneous coronary intervention for left main disease: a pooled analysis from REPLACE-2, ACUITY, and HORIZONS-AMI trials.
    Geisler T; Müller K; Karathanos A; Bocksch W; Gawaz M; Deliargyris E; Bernstein D; Lincoff AM; Mehran R; Dangas G; Stone GW
    EuroIntervention; 2014 May; 10(1):97-104. PubMed ID: 24048204
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prasugrel plus bivalirudin vs. clopidogrel plus heparin in patients with ST-segment elevation myocardial infarction.
    Schulz S; Richardt G; Laugwitz KL; Morath T; Neudecker J; Hoppmann P; Mehran R; Gershlick AH; Tölg R; Anette Fiedler K; Abdel-Wahab M; Kufner S; Schneider S; Schunkert H; Ibrahim T; Mehilli J; Kastrati A;
    Eur Heart J; 2014 Sep; 35(34):2285-94. PubMed ID: 24816809
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Economic impact of switching to bivalirudin for a primary percutaneous coronary intervention in a US hospital.
    Olchanski N; Slawsky KA; Plent S; Kado C; Cyr PL
    Hosp Pract (1995); 2010 Nov; 38(4):138-46. PubMed ID: 21068538
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Femoral vascular closure device use, bivalirudin anticoagulation, and bleeding after primary angioplasty for STEMI: results from the HORIZONS-AMI trial.
    Sanborn TA; Tomey MI; Mehran R; Généreux P; Witzenbichler B; Brener SJ; Kirtane AJ; McAndrew TC; Kornowski R; Dudek D; Nikolsky E; Stone GW
    Catheter Cardiovasc Interv; 2015 Feb; 85(3):371-9. PubMed ID: 25179260
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Meta-analysis of randomized clinical trials comparing bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitors in patients undergoing percutaneous coronary intervention and in patients with ST-segment elevation myocardial infarction.
    Nairooz R; Sardar P; Amin H; Swaminathan RV; Kim LK; Chatterjee S; Feldman DN
    Am J Cardiol; 2014 Jul; 114(2):250-9. PubMed ID: 24890986
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy and safety of bivalirudin application during primary percutaneous coronary intervention in older patients with acute ST-segment elevation myocardial infarction.
    Chen H; Yu X; Kong X; Li L; Wu J; Ma L
    J Int Med Res; 2020 Sep; 48(9):300060520947942. PubMed ID: 32985292
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Bleeding outcomes after routine transradial primary angioplasty for acute myocardial infarction using eptifibatide and unfractionated heparin: a single-center experience following the HORIZONS-AMI trial.
    Moody WE; Chue CD; Ludman PF; Chan YK; Narayan G; Millington JM; Townend JN; Doshi SN
    Catheter Cardiovasc Interv; 2013 Sep; 82(3):E138-47. PubMed ID: 23074143
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Impact of anemia on clinical outcomes of patients with ST-segment elevation myocardial infarction in relation to gender and adjunctive antithrombotic therapy (from the HORIZONS-AMI trial).
    Tsujita K; Nikolsky E; Lansky AJ; Dangas G; Fahy M; Brodie BR; Dudek D; Möckel M; Ochala A; Mehran R; Stone GW
    Am J Cardiol; 2010 May; 105(10):1385-94. PubMed ID: 20451683
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Bivalirudin Versus Heparin Anticoagulation in Transcatheter Aortic Valve Replacement: The Randomized BRAVO-3 Trial.
    Dangas GD; Lefèvre T; Kupatt C; Tchetche D; Schäfer U; Dumonteil N; Webb JG; Colombo A; Windecker S; Ten Berg JM; Hildick-Smith D; Mehran R; Boekstegers P; Linke A; Tron C; Van Belle E; Asgar AW; Fach A; Jeger R; Sardella G; Hink HU; Husser O; Grube E; Deliargyris EN; Lechthaler I; Bernstein D; Wijngaard P; Anthopoulos P; Hengstenberg C;
    J Am Coll Cardiol; 2015 Dec; 66(25):2860-2868. PubMed ID: 26477635
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparison of bivalirudin with heparin versus abciximab with heparin for primary percutaneous coronary intervention in "Real World" practice.
    Showkathali R; Davies JR; Parker M; Taggu W; Tang KH; Clesham GJ; Gamma RA; Sayer JW; Aggarwal RK; Kelly PA
    Cardiovasc Revasc Med; 2013; 14(5):289-93. PubMed ID: 23972537
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Impact of gender and antithrombin strategy on early and late clinical outcomes in patients with non-ST-elevation acute coronary syndromes (from the ACUITY trial).
    Lansky AJ; Mehran R; Cristea E; Parise H; Feit F; Ohman EM; White HD; Alexander KP; Bertrand ME; Desmet W; Hamon M; Stone GW
    Am J Cardiol; 2009 May; 103(9):1196-203. PubMed ID: 19406258
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Bleeding risk comparing targeted low-dose heparin with bivalirudin in patients undergoing percutaneous coronary intervention: results from a propensity score-matched analysis of the Evaluation of Drug-Eluting Stents and Ischemic Events (EVENT) registry.
    Bangalore S; Cohen DJ; Kleiman NS; Regev-Beinart T; Rao SV; Pencina MJ; Mauri L;
    Circ Cardiovasc Interv; 2011 Oct; 4(5):463-73. PubMed ID: 21972401
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: the BRIGHT randomized clinical trial.
    Han Y; Guo J; Zheng Y; Zang H; Su X; Wang Y; Chen S; Jiang T; Yang P; Chen J; Jiang D; Jing Q; Liang Z; Liu H; Zhao X; Li J; Li Y; Xu B; Stone GW;
    JAMA; 2015 Apr; 313(13):1336-46. PubMed ID: 25775052
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.